These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 7966134

  • 41. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G, Haskell-Luevano C, Kendall L, Bonner G, Hadley ME, Cone RD, Hruby VJ.
    J Med Chem; 2004 Mar 11; 47(6):1514-26. PubMed ID: 14998337
    [Abstract] [Full Text] [Related]

  • 42. (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice.
    Guhlke S, Wester HJ, Bruns C, Stöcklin G.
    Nucl Med Biol; 1994 Aug 11; 21(6):819-25. PubMed ID: 9234331
    [Abstract] [Full Text] [Related]

  • 43. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
    Deshmukh MV, Voll G, Kühlewein A, Mäcke H, Schmitt J, Kessler H, Gemmecker G.
    J Med Chem; 2005 Mar 10; 48(5):1506-14. PubMed ID: 15743193
    [Abstract] [Full Text] [Related]

  • 44. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
    Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, Reubi JC, Wiersinga WM, Hooijkaas H, van der Loos T.
    J Clin Endocrinol Metab; 1994 Dec 10; 79(6):1845-51. PubMed ID: 7989493
    [Abstract] [Full Text] [Related]

  • 45. Design, synthesis and biological evaluation of negatively charged ¹¹¹In-DTPA-octreotide derivatives.
    Oshima N, Akizawa H, Zhao S, Zhao Y, Nishijima K, Kitamura Y, Arano Y, Kuge Y, Ohkura K.
    Bioorg Med Chem; 2014 Feb 15; 22(4):1377-82. PubMed ID: 24457092
    [Abstract] [Full Text] [Related]

  • 46. Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide.
    Edreira M, Melendez-Alafort L, Mather SJ.
    Nucl Med Commun; 2002 May 15; 23(5):493-9. PubMed ID: 11973491
    [Abstract] [Full Text] [Related]

  • 47. Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver.
    de Jong M, Bakker WH, Breeman WA, van der Pluijm ME, Kooij PP, Visser TJ, Docter R, Krenning EP.
    J Nucl Med; 1993 Nov 15; 34(11):2025-30. PubMed ID: 8229254
    [Abstract] [Full Text] [Related]

  • 48. Somatostatin cyclic octapeptide analogs which preferentially bind to SOMa receptors block a calcium current in rat superior cervical ganglion neurons.
    Ikeda SR, Schofield GG.
    Neurosci Lett; 1989 Jan 30; 96(3):283-8. PubMed ID: 2566139
    [Abstract] [Full Text] [Related]

  • 49. Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin.
    Naydenova E, Wesselinova D, Staykova S, Goshev I, Vezenkov L.
    Anticancer Agents Med Chem; 2018 Jan 30; 18(10):1417-1424. PubMed ID: 29667555
    [Abstract] [Full Text] [Related]

  • 50. Syntheses and biological activities of sandostatin analogs containing stereochemical changes in positions 6 or 8.
    Rueter JK, Mattern RH, Zhang L, Taylor J, Morgan B, Hoyer D, Goodman M.
    Biopolymers; 2000 May 30; 53(6):497-505. PubMed ID: 10775065
    [Abstract] [Full Text] [Related]

  • 51. Concise site-specific synthesis of DTPA-peptide conjugates: application to imaging probes for the chemokine receptor CXCR4.
    Masuda R, Oishi S, Ohno H, Kimura H, Saji H, Fujii N.
    Bioorg Med Chem; 2011 May 15; 19(10):3216-20. PubMed ID: 21524584
    [Abstract] [Full Text] [Related]

  • 52. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Decristoforo C, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R, Mather SJ.
    Eur J Nucl Med; 2000 Oct 15; 27(10):1580. PubMed ID: 11083550
    [No Abstract] [Full Text] [Related]

  • 53. A refined model for the somatostatin pharmacophore: conformational analysis of lanthionine-sandostatin analogs.
    Melacini G, Zhu Q, Osapay G, Goodman M.
    J Med Chem; 1997 Jul 04; 40(14):2252-8. PubMed ID: 9216844
    [Abstract] [Full Text] [Related]

  • 54. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bonavolonta G, Muto P, Lombardi G, Fenzi G.
    J Clin Endocrinol Metab; 1998 Nov 04; 83(11):3790-4. PubMed ID: 9814448
    [Abstract] [Full Text] [Related]

  • 55. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
    Pelton JT, Kazmierski W, Gulya K, Yamamura HI, Hruby VJ.
    J Med Chem; 1986 Nov 04; 29(11):2370-5. PubMed ID: 2878079
    [Abstract] [Full Text] [Related]

  • 56. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.
    Rogers BE, Zinn KR, Lin CY, Chaudhuri TR, Buchsbaum DJ.
    Cancer; 2002 Feb 15; 94(4 Suppl):1298-305. PubMed ID: 11877760
    [Abstract] [Full Text] [Related]

  • 57. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb 15; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 58. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer.
    Stolz B, Smith-Jones P, Albert R, Tolcsvai L, Briner U, Ruser G, Mäcke H, Weckbecker G, Bruns C.
    Digestion; 1996 Feb 15; 57 Suppl 1():17-21. PubMed ID: 8813461
    [Abstract] [Full Text] [Related]

  • 59. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.
    Kazmierski W, Wire WS, Lui GK, Knapp RJ, Shook JE, Burks TF, Yamamura HI, Hruby VJ.
    J Med Chem; 1988 Nov 15; 31(11):2170-7. PubMed ID: 2903246
    [Abstract] [Full Text] [Related]

  • 60. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies.
    Pearson DA, Lister-James J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Taylor JE, Moyer BR, Dean RT.
    J Med Chem; 1996 Mar 29; 39(7):1361-71. PubMed ID: 8691466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.